Introduction
Granulocyte colony stimulating factor (G-CSF) has been identified as a cytokine that induces proliferation of normal granulocyte colonies and maturation of leukemic cell lines. [1] [2] [3] Recombinant human G-CSF (rhG-CSF) has been in clinical use for more than 20 years to reduce neutropenia after radiation and chemotherapy. Furthermore, rhG-CSF is approved for mobilizing peripheral blood progenitor cells from healthy donors and is used worldwide in hematopoietic stem cell transplantation. 4, 5 Growing evidence exists that G-CSF not only acts as a master regulator of hematopoiesis and the innate immune system, but also exerts pleiotropic effects on adaptive immune responses. In patients 6 and healthy stem cell donors 7 treated with rhG-CSF, the proliferative response of T cells to allogeneic and mitogenic stimulation is reduced. This effect is thought to be mediated by soluble factors, 8, 9 indirect modulation of monocyte function, 7, 10 or inhibition of costimulatory signaling pathways. 11 Further investigations by our group have shown that G-CSF provokes a shift toward Th2 immune response via the functional expression of the G-CSF receptor on T lymphocytes, 12 with an induction of IL4 secretion in vitro and in vivo. Others have identified increases in IL10, 13, 14 IL4, [15] [16] [17] TGF β 18 production, and decreases in IFN-γ and IL2 15, 17, 19, 20 on alloantigenic or mitogenic stimulation. Most of these data argue for an indirect effect of G-CSF on the T-cell phenotype via monocytes and dendritic cells. Rutella and associates have shown that G-CSF induces CD4 + T cells with a regulatory phenotype producing high amounts of IL10, and to a lesser extent, TGF-β in the periphery of healthy human recipients. 14 These regulatory T cells (Tr1 cells) might convert from CD4 + CD25 -T cells 21 in the presence of IL10 and suppress inflammatory immune responses 22 like graft-versus-host disease.
Experimental data and clinical trials have shown the potency of regulatory T cells to suppress graftversus-host disease [23] [24] [25] while preserving the beneficial graft-versus-leukemia effect. 26, 27 Notably, regulatory T cells (Tregs) also play a pivotal role in controlling immune responses in autoimmunity, solid-organ transplantation, and infectious diseases. Therefore, the therapeutic application of Tregs to suppress unwanted immune reactions is under investigation. 28 A major limitation for a broad clinical application of adoptive regulatory T cells (Treg) cell transfer is the small number of Tregs in the peripheral blood of healthy donors. Therefore, establishing large-scale expansion protocols for human Tregs is in the focus of clinical research. In the context of clinical developments in cell-based therapies and with respect to formerly reported results, we addressed the question whether G-CSF may directly induce conversion of naïve T cells into regulatory T cells. The direct induction of Tregs by G-CSF may effect development of novel strategies for Treg cell induction and expansion.
Materials and Methods

Donor sampling
Heparinized blood samples (40 mL) were obtained from 28 healthy donors (17 women and 11 men; median age 31.5 y; range 20-48 y) after gaining written, informed consent. Approval was obtained from the ethical committee of Hannover Medical School. All protocols conformed with the ethical guidelines of the 1975 Helsinki Declaration.
Isolation of CD4 + CD25 -T lymphocytes and stimulation with recombinant human granulocyte colony stimulating factor Peripheral blood mononuclear cells were freshly isolated by Ficoll gradient and CD4 + CD25 -T lymphocytes were negative selected using the CD4 + CD25 + regulatory T cell kit (Miltenyi Biotech, Germany) according to the manufacturer's protocol. The purity of the isolated T cell population was controlled by fluorescent-activated cell sorter analysis (> 95%). CD4 + CD25 -T lymphocytes were stimulated with/without 100 ng/mL rhG-CSF (Granocyte 13, Chugai Pharma, Frankfurt, Germany) on anti-CD3 and anti-CD28 antibody precoated cell culture plates (over night at 4°C with 5 μg/mL) for the indicated time points. Total RNA was isolated using RNeasy Mini Kit from Qiagen (Hilden, Germany) and DNase digested according to the manufacturer's protocol. Isolated mRNA was reversely transcribed using 200 U Superscript II (Invitrogen, Germany), oligo dT-, and random hexamer primers (Invitrogen). Polymerase chain reaction was performed using primers specific for human RPS9, Foxp3, CD127, CTLA-4, GATA3, CD39, and IL10 (primer sequences could be requested by the corresponding author). Quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR) was done with the GeneAmp 5700 Sequence Detection System (Perkin Elmer, Rodgau Jügesheim, Germany) using Brilliant SYBR Green QPCR Core Reagent Kit (Stratagene, Heidelberg, Germany) as described elsewhere. 29 
Regulatory T cell suppression assay
To test whether G-CSF induces a suppressive phenotype CD4 + CD25 -T cells were prestimulated with 100 ng/mL G-CSF on anti-CD3 and anti-CD28 precoated cell culture plates for 12 hours and cultured at a ratio of 1:1 with CD4 + CD25 -T cells for additional 12 hours. Proliferation assays were done in triplicates in 200 μL of RPMI medium that contained 10% fetal calf serum and pulsed with 1 μCi/well of [3H]-thymidine for the final 6 hours.
[3H]-Thymidine incorporation was measured by scintillation counting.
Regulatory T cell phenotype analysis
In vitro cultured and stimulated CD4 + CD25 -T cells were treated for the last 4 hours of cell culture stimulation with the protein transport inhibitor Brefeldin A (final concentration 10 μg/mL). Staining was performed by direct immunofluorescence with monoclonal antibodies against the antigens with following fluorochromes: CD4 PerCP, CD127 Alexa647, Foxp3 Alexa488, CD25 PeCy7, CD39 APC, CTLA4 PE, membrane bound TGFß [LAP] APC, 4-1BB APC, CD62L PE, IL10 PE, Helios PE, and CD69 APC Cy7 (BD Biosciences, Heidelberg, Germany, and BioLegend, San Diego, CA, USA). Isotype and fluorescence minus one controls were included for the respective antibodies. Fixation and permeabilization for staining with antibodies against Foxp3, Helios, CTLA4, and IL10 were done with Foxp3 buffer set (BD Biosciences). After surface staining cells were incubated with Fixation Buffer A for 15 minutes, they were washed twice. Fixed cells were permeabilized by incubating them with Buffer C for 30 minutes and stained with Foxp3, Helios, CTLA4, and IL10 antibodies. Cells were analyzed using fluorescentactivated cell sorter Canto (BD Biosciences) and FloJo software (TreeStar Inc., Ashland, OR, USA).
T cell in vitro expansion
Isolated CD4 + CD25 -T cells were cultured in RPMI 1640 containing GlutaMAX medium (Invitrogen, Darmstadt, Germany) supplemented with 10% fetal calf serum (Biochrom AG, Berlin, Germany) for 14 days at 37°C in 96-well U-bottom plates. To avoid contaminations, 50 μg/mL gentamycin (Sigma Aldrich, Hamburg, Germany) and 50 μg/mL penicillin/streptomycin (Sigma Aldrich) were added to the medium. T cells were stimulated daily with 100 ng/mL rhG-CSF (Granocyte 13, Chugai Pharma, Frankfurt, Germany) and IL-2 500 U/mL (PeproTech GmbH, Hamburg, Germany) and CD3/CD28 Dynabeads (Invitrogen, Darmstadt, Germany) in a 4:1 ratio, according to expansion protocols. 30 Dynabeads were changed after 7 days and removed after 11 days' culture.
statistical analyses
For statistical analyses, GraphPad Prism software (GraphPad software Inc, La Jolla, CA, USA) using paired or unpaired t test was used. A P value of < .05 was considered statistically significant. Error bars represent standard error of the mean.
Results
gene expression analysis of T cells after granulocyte colony stimulating factor stimulation in vitro
The following experiments were performed to determine whether G-CSF stimulation in vitro converts CD4 + CD25 − T cells into a Foxp3 + regulatory T cell phenotype. In a kinetic study, CD4 + CD25-T cells were analyzed 2, 4, 12, and 24 hours after stimulation with anti-CD3 and anti-CD28 for Foxp3 gene expression changes with and without additional G-CSF application. As demonstrated in Figure 1 , in vitro stimulation of CD4 + CD25 -T lymphocytes led to an up-regulation of Foxp3, independent of G-CSF application. However, quantitative analysis of further Treg cell-associated gene transcripts ( Figure 2 ) displayed a significant down-regulation of CD127 and up-regulation of CTLA-4 and CD39 in anti-CD3 and anti-CD28 stimulated naïve T cells with and without G-CSF compared with cultured counterparts without any stimulation. Up-regulation of CTLA4 is significantly more pronounced in stimulated T cells without addition of G-CSF, whereas the significant change in gene expression levels for CD127 and CD39 is not G-CSF dependent. Former results were confirmed, 12 and CD4 + T cells showed significantly higher mRNA expression levels for the Th2 master regulator 
Immune phenotype of T cells after granulocyte colony stimulating factor stimulation in vitro
In addition, effects of G-CSF stimulation on the immune phenotype of anti-CD3 and anti-CD28 stimulated naïve T cells were studied ( Figure 3 ) for markers associated with Treg cell differentiation/determination (CD127, Helios, Foxp3) and function (CD39, CTLA-4, IL-10, LAP), T-cell activation/costimulation (4-1BB, CD62L, CD69), and differentiation (CD45RA, CD45RO). In vitro activation with anti-CD3 and anti-CD28 stimulation led to a conversion of CD4 + CD25 -T cells to CD25 + T cells (data not shown). However, the additional stimulation with G-CSF did not reveal any significant changes in the expression of the analyzed phenotypic Treg and T cell markers. The stimulated T cells show signs of activation (CD69, CD62L) and express membrane bound TGFß. Less than 20% show a naïve T cell phenotype (CD45RA) whereas approximately 10% resemble a memory T cell phenotype (CD45RO). An induction of Foxp3 protein expression was not observed. Moreover, expression of other Treg cell-associated marker molecules was not affected after in vitro stimulation with and without G-CSF.
Effects of granulocyte colony stimulating factor on the proliferation of T cells
To test whether G-CSF can enhance the proliferation of T cells, long-term expansion cultures with anti-CD3 and anti-CD28 stimulation under IL2 supplementation have been performed. Cell numbers of highly purified CD4 + CD25 -T cells increased up to 7.5 and 9.8 fold (means, 3.0 and 3.5 fold) without and with additional G-CSF stimulation in vitro ( Figure 4A ; P < .05). Thus, direct G-CSF stimulation of T cells does not induce cell
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-T Cells proliferation under the described conditions. In addition, the phenotypic fluorescent-activated cell sorter analysis of CD4 + T cells after 14 days of in vitro culture without and with G-CSF did not affect the expression levels of Treg cell-associated molecules Foxp3 (mean, 7.7% and 6.6% Foxp3 + ) and CD127 (mean, 49.3% and 44.3% CD127 -) ( Figure 4B ).
Functional analysis of granulocyte colony stimulating factor-treated T cells
Regulatory T cells display a suppressive phenotype and show an inhibition on the proliferation of effector T cells. To test functional effects of direct G-CSF stimulation, G-CSF pretreated T cells were studied in a standard assay for their suppressive capacity. Figure 5 shows that co-incubation of G-CSF pretreated T cells with effector T cells did not lead to an inhibition on effector T-cell proliferation.
Discussion
Regulatory T cells play a pivotal role in inducing and maintaining immune tolerance. Several experimental and clinical studies have shown that adoptive transfer of donor regulatory T cells prevents graft-versus-host disease and favors immune reconstitution after allogeneic stem cell transplants. 24, 26, 27, 31 However, this novel cellular approach for tolerance induction is limited by the availability of small Treg cell numbers and therefore, adoptive Treg cell transfer is restricted to single applications in the lymphopenic situation of allogeneic stem cell transplantation. In vitro induction and expansion of Tregs might overcome these limitations. The availability of higher Treg cell numbers would allow repetitive Treg cell infusions in stem cell transplantation or even, application in the nonlymphopenic situation of solid organ transplantation. We evaluated the potential of G-CSF for in vitro induction and expansion of Tregs.
In the present study, we evaluated the potential of G-CSF for in vitro induction and subsequent expansion of Tregs. Growing evidence indicates that G-CSF-induced effects are not limited to the myeloid lineage, 4 but also induce pleiotropic modulations of adaptive immune responses. 32 This may be reflected by the functional expression of the G-CSF receptor in other cell types like T lymphocytes. 12 Most importantly, G-CSF induces alterations of cytokine networks, 19, 33 polarization of T cell function, 15, 17, 34, 35 and augmentation of IL10-producing Tregs. 36, 37 Recent research has identified several promising candidates promoting the in vivo and/or in vitro induction/expansion of Tregs. The immunosuppressive agent rapamycin provides a selective advantage for Treg cell growth, 38 whereas all-trans retinoic acid facilitates de novo generation of Foxp3 + Tregs from CD25 -T cells. 39 This conversion to Tregs also can be achieved in vitro in the presence of alltrans retinoic acid and transforming growth factor beta. 40, 41 As high and stable Foxp3 expression is mandatory for the suppressive function of Tregs, [42] [43] [44] the hypomethylating agents decitabine and azacitidine emerged as promising FDA (Food and Drug Administration) approved drugs to induce Foxp3 expression in CD4 + CD25 -T cells in vitro and in vivo. Induction of Foxp3 in activated CD4 + CD25 -T cells generated functional Tregs with suppressive properties. Moreover, in vivo treatment of mice with azacitidine after allogeneic stem cell transplantation mitigates graft-versus-host disease while preserving graft versus leukemia by increased peripheral conversion of CD4 + CD25 -effector T cells into functionally suppressive Foxp3 + Tregs. 45 Although G-CSF stimulation of CD4 + CD25 -T cells results in short-term induction of Foxp3 173 Proliferation presented as means of counts per minute and was measured in in vitro anti-CD3/CD28 stimulated CD4 + CD25 -T lymphocytes isolated from 5 healthy donors (grey bar). Inhibition assay was performed by using CD4 + CD25 -T lymphocytes prestimulated with G-CSF for 12 hours and co-cultured afterwards at a ratio of 1:1 with activated CD4 + CD25 -T cells for additional 12 hours (black bar). Results of a 2-tailed unpaired t test > .05 were regarded as not significant (ns). 
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-T Cells mRNA expression, this effect could not be observed at the protein level. Most importantly, functional analyses reveal that G-CSF stimulation of CD4 + CD25 -T cells in vitro do not induce an immune regulatory phenotype with suppressive potency. This observation is supported by the expression patterns of molecules associated with the suppressive function of Tregs like CD39 46 and TGFβ binding protein LAP. 47 Low expression of LAP results in higher secretion of TGFβ and thus, enhancement of suppression. 48 However, LAP is highly expressed after G-CSF stimulation in vitro, indicating a lower secretion of TGFβ, which is well in line with former results studying in vivo effects of G-CSF. 14 Furthermore, G-CSF stimulation of CD4 + CD25 -T cells did not reduce expression of the IL7 receptor (CD127), also arguing against a suppressive phenotype as the expression level of CD127 is negatively correlating with the suppressive function of Tregs. 49 Interestingly, treatment of mononuclear cells with rabbit antithymocyte globulin leads to expansion of functional Tregs by converting CD4 + CD25 -T cells to CD4 + CD25 + T cells with increased Foxp3 expression and IL10 secretion. 50 Whereas rabbit antithymocyte globulin induces expression of GITR and CTLA4, 51 G-CSF treatment results in decreased mRNA expression levels of these activation/costimulatory marker molecules. In addition, protein expression of CD62L, CD69, and 4-1BB remained unaffected by G-CSF. Rutella and associates detected signs of T cell activation and the induction of a Tr1 phenotype after G-CSF stimulation in vivo with high secretion of IL10, 14 which we did not detect. In contrast, we demonstrate that direct G-CSF stimulation induces GATA3 and IL4 expression in donor CD4 + T cells after G-CSF treatment. 12 Moreover, CD4 + T cells maintained their Foxp -CD127 + phenotype also after repetitive G-CSF stimulation in vitro.
Formerly reported induction of Tregs after G-CSF application in vivo does not result from direct G-CSF stimulation of CD4 + CD25 -T cells. Therefore, G-CSF does not qualify for the induction and subsequent expansion of regulatory T cells in vitro under the described conditions. The development of cellular strategies for tolerance induction in hematopoietic stem cell and solid organ transplantation must rely on candidates other than G-CSF for efficient in vitro induction/expansion of Tregs.
